{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:55:06Z","timestamp":1792814106523,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Becton, Dickinson and Company"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ygyno.2019.05.012","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T17:08:48Z","timestamp":1559322528000},"page":"360-367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, \u226521\u202fyears of age, with ASC-US or LSIL cytology"],"prefix":"10.1016","volume":"154","author":[{"suffix":"Jr","given":"Thomas C.","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Stoler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Parvu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Yanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.05.012_bb0005","series-title":"Cytopathology Checklist","author":"College of American Pathologists","year":"2017"},{"key":"10.1016\/j.ygyno.2019.05.012_bb0010","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/LGT.0b013e318287d329","article-title":"2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors","volume":"17","author":"Massad","year":"2013","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.ygyno.2019.05.012_bb0015","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1097\/LGT.0b013e3182854253","article-title":"Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results","volume":"17","author":"Katki","year":"2013","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.ygyno.2019.05.012_bb0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ygyno.2010.04.013","article-title":"Clinical validation of the Cervista HPV HR and 16\/18 genotyping tests for use in women with ASC-US cytology","volume":"118","author":"Einstein","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.05.012_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2012.12.003","article-title":"APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results","volume":"208","author":"Stoler","year":"2013","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2019.05.012_bb0030","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1309\/AJCPZ5JY6FCVNMOT","article-title":"High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study","volume":"135","author":"Stoler","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ygyno.2019.05.012_bb0035","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/ajcp\/aqx091","article-title":"Performance of the cobas HPV test for the triage of atypical squamous cells of undetermined significance cytology in cervical specimens collected in SurePath","volume":"148","author":"Tewari","year":"2017","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ygyno.2019.05.012_bb0040","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/ajcp\/aqy084","article-title":"Detection of cervical neoplasia by human papillomavirus testing in an atypical squamous cells-undetermined significance population results of the Becton Dickinson Onclarity trial","volume":"151","author":"Wright","year":"2019","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ygyno.2019.05.012_bb0045","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1158\/1055-9965.EPI-12-1455","article-title":"Risk of precancer determined by HPV genotype combinations in women with minor cytologic abnormalities","volume":"22","author":"Gage","year":"2013","journal-title":"Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"key":"10.1016\/j.ygyno.2019.05.012_bb0050","first-page":"4197","article-title":"Utility of human papillomavirus genotyping for triage of patients with atypical squamous cells of undetermined significance by cervical cytology","volume":"35","author":"Lee","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2019.05.012_bb0055","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2015.06.040","article-title":"A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results","volume":"138","author":"Schiffman","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.05.012_bb0060","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1097\/LGT.0b013e3182854269","article-title":"Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results","volume":"17","author":"Katki","year":"2013","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.ygyno.2019.05.012_bb0065","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/jnci\/92.5.397","volume":"92","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2019.05.012_bb0070","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1097\/LGT.0b013e318285423c","article-title":"Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines","volume":"17","author":"Katki","year":"2013","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.ygyno.2019.05.012_bb0075","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ygyno.2018.04.007","article-title":"The Onclarity human papillomavirus trial: design, methods, and baseline results","volume":"149","author":"Stoler","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.05.012_bb0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2018.12.024","article-title":"Stratified risk of high-grade cervical disease using Onclarity HPV extended genotyping in women, \u226525\u202fyears of age, with NILM cytology","volume":"153","author":"Stoler","year":"2019","journal-title":"Gyn Onc"},{"key":"10.1016\/j.ygyno.2019.05.012_bb0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1309\/AJCP53KMHNRDICBL","article-title":"Clinical performance of the BD Onclarity HPV assay using an adjudicated cohort of BD SurePath liquid-based cytology specimens","volume":"142","author":"Wright","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ygyno.2019.05.012_bb0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pvr.2016.01.003","article-title":"Clinical and analytical performance of the BD Onclarity HPV assay for detection of CIN2+ lesions on SurePath samples","volume":"2","author":"Ejegod","year":"2016","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.ygyno.2019.05.012_bb0095","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.287.16.2114","article-title":"The 2001 Bethesda system: terminology for reporting results of cervical cytology","volume":"287","author":"Solomon","year":"2002","journal-title":"Jama"},{"key":"10.1016\/j.ygyno.2019.05.012_bb0100","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.5858\/arpa.LGT200570","article-title":"The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology","volume":"136","author":"Darragh","year":"2012","journal-title":"Archives of Pathology & Laboratory Medicine"},{"key":"10.1016\/j.ygyno.2019.05.012_bb0105","article-title":"Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results","volume":"17","author":"Katki","year":"2013","journal-title":"Journal of Lower Genital Tract Disease"},{"key":"10.1016\/j.ygyno.2019.05.012_bb0110","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/LGT.0000000000000103","article-title":"Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance","volume":"19","author":"Huh","year":"2015","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.ygyno.2019.05.012_bb0115","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1309\/AJCPTGD94EVRSJCG","article-title":"American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer","volume":"137","author":"Saslow","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ygyno.2019.05.012_bb0120","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.ygyno.2019.05.012_bb0125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jcv.2014.02.002","article-title":"Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions","volume":"60","author":"Cuzick","year":"2014","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.ygyno.2019.05.012_bb0130","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/ijc.28605","article-title":"The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: a population-based study of opportunistic cervical screening in the United States","volume":"135","author":"Wheeler","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.05.012_bb0135","first-page":"255","article-title":"Human Papillomaviruses","author":"International Agency for Research on Cancer","year":"2012","journal-title":"IARC Monogr. Eval. Carcinog. Risks Hum."},{"key":"10.1016\/j.ygyno.2019.05.012_bb0140","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ygyno.2019.02.016","article-title":"HPV infections and cytologic abnormalities in vaccinated women 21\u201334\u202fyears of age: results from the baseline phase of the Onclarity trial","volume":"153","author":"Wright","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.05.012_bb0145","article-title":"Role of screening history in clinical meaning and optimal management of positive cervical screening results","author":"Castle","year":"2018","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819312569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819312569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:47:08Z","timestamp":1758772028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819312569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0090825819312569"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.05.012","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, \u226521\u202fyears of age, with ASC-US or LSIL cytology","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}